ArticleMedizinische Klinik (Munich, Germany : 1983)2009
[Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].
Article in Medizinische Klinik (Munich, Germany : 1983), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- [Sustainable reimbursement of the B‑centres for rare diseases in Germany-status quo and solution approaches].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Article
- [Cystic fibrosis : A new disease pattern in adult medicine].Der Internist · 2018Review
- Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study.JMIR research protocols · 2018Article
- Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.PharmacoEconomics · 2012Article
- Staff costs of hospital-based outpatient care of patients with cystic fibrosis.Health economics review · 2011Article
- [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].Medizinische Klinik (Munich, Germany : 1983) · 2010Article
- [Analysis of costs and profits of ambulatory care of Marfan patients after initiation of a novel German legal directive (116 b SGB V)].Medizinische Klinik (Munich, Germany : 1983) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMain objective of this study is to assess and evaluate resource use in outpatient treatment of cystic fibrosis (CF) in Germany and to compare this with current reimbursement.
methodsOutpatient treatment was evaluated in seven different CF centers.Clinical patient data, resource use, and time consumption were recorded in 2006. A micro-costing approach was used to price resource use data.
resultsMean costs of 488 Euros per patient (n = 326) and quarter occurred. Remuneration (252 Euros per patient/quarter) covered only 52% of the total costs. Furthermore, a considerable time and financial burden for patients as well as decreasing quality of life with increasing age were found. Costs for medication came to 21,604 Euros per patient/year.
conclusionHuman resources in German CF centers today already are below the requirements set by the European consensus for standards of CF care. It will be crucial in assuring a high level of patient care to reach a cost-covering reimbursement scheme in Germany.
Indexed as
Identifiers
19618138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.